Stromal biology and therapy in pancreatic cancer
暂无分享,去创建一个
Malte Buchholz | Christine Feig | Patrick Michl | Natalie Cook | D. Tuveson | T. Gress | M. Buchholz | K. Olive | P. Michl | K. Frese | M. Jacobetz | M. Lolkema | A. Neesse | C. Feig | Kenneth P Olive | N. Cook | Thomas M Gress | Albrecht Neesse | David A Tuveson | Kristopher K Frese | Mike A Jacobetz | Martijn P Lolkema | Michael A. Jacobetz
[1] Douglas B. Evans,et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.
[2] S. Kern,et al. Molecular genetic basis of pancreatic adenocarcinoma , 1999, Genes, chromosomes & cancer.
[3] G. Bratthauer,et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. , 2000, Cancer research.
[4] T. Adrian,et al. Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through the MAP kinase pathway. , 2004, Biochemical and biophysical research communications.
[5] T. Ratliff. TGF-Beta Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004 .
[6] Helmut Friess,et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] W. Nealon,et al. Inflammatory Mechanisms Contributing to Pancreatic Cancer Development , 2004, Annals of surgery.
[8] P. Bycott,et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study , 2008, The Lancet.
[9] T. Brentnall. Management strategies for patients with hereditary pancreatic cancer , 2005, Current treatment options in oncology.
[10] M. Hidalgo,et al. Development of matrix metalloproteinase inhibitors in cancer therapy. , 2001, Journal of the National Cancer Institute.
[11] W. Scheithauer,et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Helmut Friess,et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. , 2009, Neoplasia.
[13] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.
[14] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[15] N. Kojima,et al. Vitamin A-storing cells (stellate cells). , 2007, Vitamins and hormones.
[16] J. Cameron,et al. Improved hospital morbidity, mortality, and survival after the Whipple procedure. , 1987, Annals of surgery.
[17] M. Korsten,et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture , 1998, Gut.
[18] T. Gress,et al. Pancreatic Stellate Cells Potentiate Proinvasive Effects of SERPINE2 Expression in Pancreatic Cancer Xenograft Tumors , 2007, Pancreatology.
[19] W. Scheithauer,et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Daniel G Haller,et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Iacobuzio-Donahue,et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Einsele,et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T. Ohtsuka,et al. Tumor–stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c‐Met pathway , 2006, International journal of cancer.
[24] J. Nemunaitis,et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer , 2002, British Journal of Cancer.
[25] M. Bachem,et al. Pancreatic stellate cells—role in pancreas cancer , 2008, Langenbeck's Archives of Surgery.
[26] K. Syrigos,et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer , 2006, British Journal of Cancer.
[27] W. Miller,et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Hans A. Kestler,et al. Transcriptome analysis of human hepatic and pancreatic stellate cells: organ-specific variations of a common transcriptional phenotype , 2005, Journal of Molecular Medicine.
[29] M. Shekhar,et al. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. , 2001, Cancer research.
[30] D. V. Von Hoff,et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] G. Colucci,et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma , 2002, Cancer.
[32] M. Korsten,et al. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover , 2003, Gut.
[33] R. Schmid,et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. , 1998, Gastroenterology.
[34] Tomas Mitkus,et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. , 2007, Gastroenterology.
[35] P. Catalano,et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Zalupski,et al. Optimum Cytotoxic Therapy for Advanced Pancreatic Cancer , 2008 .
[37] J. Dancey,et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] T. Seufferlein,et al. Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay , 2007, Journal of Cell Science.
[39] R. Hruban,et al. An In vivo Platform for Translational Drug Development in Pancreatic Cancer , 2006, Clinical Cancer Research.
[40] Alison P. Klein,et al. Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.
[41] R. Schilsky,et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB , 2007 .
[42] T. Fukuda,et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma , 2000, Cancer.
[43] Murray Korc,et al. Pancreatic cancer-associated stroma production. , 2007, American journal of surgery.
[44] A. Dachman,et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Gerald C. Chu,et al. Stromal biology of pancreatic cancer , 2007, Journal of cellular biochemistry.
[46] Hidetaka Mochizuki,et al. The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness: Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2004, Pancreas.
[47] D. V. Von Hoff,et al. Tumor-stroma interactions in pancreatic ductal adenocarcinoma , 2007, Molecular Cancer Therapeutics.
[48] M. Washington,et al. TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.
[49] R. Kuick,et al. The Molecular Basis of Pancreatic Fibrosis: Common Stromal Gene Expression in Chronic Pancreatitis and Pancreatic Adenocarcinoma , 2004, Pancreas.
[50] A. Rosemurgy,et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] R. Hruban,et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.
[52] M. Osman,et al. Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness , 2009, Clinical Cancer Research.
[53] H. Saeger,et al. Survival After Pancreatoduodenectomy: 118 Consecutive Resections Without an Operative Mortality , 1990, Annals of surgery.
[54] M. Omary,et al. The pancreatic stellate cell: a star on the rise in pancreatic diseases. , 2007, The Journal of clinical investigation.
[55] K. Wong,et al. Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133+ Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma , 2008, Stem cells.
[56] David Goldstein,et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. , 2008, Cancer research.
[57] Seung‐Mo Hong,et al. Overexpression of Smoothened Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancer–Associated Fibroblasts , 2010, Clinical Cancer Research.
[58] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[59] H. Friess,et al. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma , 2008, Cancer biology & therapy.
[60] P. Hein,et al. Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.
[61] Gregory Y. Lauwers,et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis , 2003, Nature.
[62] D. V. Von Hoff,et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] E. Petricoin,et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.
[64] A. Buck,et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. , 2005, Gastroenterology.
[65] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] G. Gaviraghi,et al. Successful xenografting of cryopreserved primary pancreatic cancers , 2001, Virchows Archiv.
[67] U. Boggi,et al. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. , 2004, European journal of pharmacology.
[68] S. Pandol,et al. Extracellular matrix proteins protect pancreatic cancer cells from death via mitochondrial and nonmitochondrial pathways. , 2003, Gastroenterology.
[69] J. Neoptolemos,et al. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. , 1996, British Journal of Cancer.
[70] V. Shah,et al. Interplay of Tumor Microenvironment Cell Types with Parenchymal Cells in Pancreatic Cancer Development and Therapeutic Implications , 2009, Journal of gastrointestinal cancer.
[71] Eileen M O'Reilly,et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] David Cameron,et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.
[73] L. Way,et al. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. , 1993, American journal of surgery.
[74] D. Tuveson,et al. The use of GEM models for experimental cancer therapeutics , 2008, Disease Models & Mechanisms.
[75] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[76] E. Furth,et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. , 2006, Cancer research.
[77] Hua Tian,et al. A paracrine requirement for hedgehog signalling in cancer , 2008, Nature.
[78] M. Barbacid,et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. , 2007, Cancer cell.
[79] Thomas G. Caffery,et al. Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer , 2008, Clinical Cancer Research.
[80] M. Goggins,et al. Gene Expression Profiling of Tumor–Stromal Interactions between Pancreatic Cancer Cells and Stromal Fibroblasts , 2004, Cancer Research.
[81] F. Rödel,et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma , 2008, Cancer biology & therapy.
[82] M. Christian,et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.
[83] Pamela S. Robinson,et al. Epidermal growth factor receptor regulates pancreatic fibrosis. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[84] R. Hruban,et al. Treatment of familial pancreatic cancer and its precursors , 2005, Current treatment options in gastroenterology.
[85] J. Neoptolemos,et al. The Matrix Metalloproteinases and Their Inhibitors in the Treatment of Pancreatic Cancer , 1999, Annals of the New York Academy of Sciences.
[86] R. Hruban,et al. Genetic progression in the pancreatic ducts. , 2000, The American journal of pathology.
[87] P. Platzer,et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. , 2007, The New England journal of medicine.
[88] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] Takeshi Iwamura,et al. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. , 2003, Cancer research.
[90] R. Labianca,et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] Robert D. Cardiff,et al. Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis , 2005, Cell.
[92] T. Gress,et al. Role of Extracellular Matrix in Pancreatic Diseases , 1998, Digestion.
[93] H. Friess,et al. Role of MT‐MMPs and MMP‐2 in pancreatic cancer progression , 2000, International journal of cancer.
[94] G. Adler,et al. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. , 2006, Cancer research.
[95] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[96] H. Tian,et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis , 2009, Proceedings of the National Academy of Sciences.
[97] J S Wilson,et al. Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells , 2004, Pancreas.